AstraZeneca on Thursday said the European Commission had signed off on the use of Bevespi throughout the bloc, making it the first medicine in its class to be approved by the EC.
The group said the approval of Bevespi, a pressurised metered-dose inhaler aimed at relieving symptoms in adult patients with chronic obstructive pulmonary disease, offered patients with COPD “an important new choice” when it comes to inhaler devices.
AstraZeneca’s head of respiratory and global medicines development Dr Colin Reisner said: “Bevespi Aerosphere is already available to COPD patients in the US and other countries, and this approval means we can now bring this new medicine to patients in Europe.”
Dr Omar Usmani, a consultant physician in respiratory medicine at the National Heart and Lung Institute, added: “Bevespi Aerosphere is an important treatment option in COPD, particularly for patients with limited lung function and advanced age who may benefit from using a pMDI.”
